Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study
Luigi Liguori, Gabriele Giorgio, Giovanna Polcaro, Valentina Pagliara, Domenico Malandrino, Francesco Perri, Marco Cascella, Alessandro Ottaiano, Valeria Conti, Alberto Servetto, Roberto Bianco, Stefano Pepe, Francesco Sabbatino · 2024
Read Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study by Luigi Liguori, Gabriele Giorgio, Giovanna Polcaro, Valentina Pagliara, Domenico Malandrino, Francesco Perri, Marco Cascella, Alessandro Ottaiano, Valeria Conti, Alberto Servetto, Roberto Bianco, Stefano Pepe, Francesco Sabbatino (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11631946.txt.
Description
Luigi Liguori and co-authors review real-world results of checkpoint immunotherapy for non-small cell lung cancer. Drugs that block the PD-1 or PD-L1 proteins have reshaped care for solid tumors, and trials show gains in survival and quality of life. Yet some patients gain nothing, and trial rules can skew who is studied.
Their 2024 study pulls the charts of patients treated at one Italian university hospital over eight years. Patients got a checkpoint drug alone or with chemotherapy. The team tests links between patient and tumor traits and both safety and survival outcomes. Real-world checks like this one help find markers that predict who will benefit and where trial claims need care.
Catalog record
| CREATOR | Luigi Liguori, Gabriele Giorgio, Giovanna Polcaro, Valentina Pagliara, Domenico Malandrino, Francesco Perri, Marco Cascella, Alessandro Ottaiano, Valeria Conti, Alberto Servetto, Roberto Bianco, Stefano Pepe, Francesco Sabbatino |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |